Deciphering the AMPK–SQSTM1 Feedback Loop in Metabolic Stress Adaptation

Study Background and Research Question

Metabolic and oxidative stresses are hallmarks of the tumor microenvironment, where nutrient depletion and reactive oxygen species (ROS) accumulation challenge cancer cell survival. Central to the cellular response are the STK11/LKB1–AMPK pathway, which maintains energy and redox homeostasis, and the KEAP1–NFE2L2/NRF2 pathway, the master regulator of antioxidant defense. In non-small cell lung cancers (NSCLC) with co-occurring mutations in KEAP1 and STK11/LKB1, aberrant activation of NFE2L2/NRF2 is thought to compensate for impaired AMPK signaling, but the molecular crosstalk and adaptive mechanisms remain poorly understood. The research question addressed by Choi et al. (AUTOPHAGY 2024) centers on how metabolic stress orchestrates the activation and feedback regulation of AMPK and NFE2L2/NRF2 via SQSTM1/p62, and what this means for tumor adaptation and therapeutic targeting.

Key Innovation from the Reference Study

The pivotal innovation reported in this study is the identification of a double-positive feedback loop between AMPK and SQSTM1/p62 in the context of metabolic stress. This loop enables dual activation of AMPK and NFE2L2/NRF2, synergistically boosting antioxidant defense capacity in stressed cells. The researchers demonstrate that SQSTM1/p62 is not only a downstream effector but also an upstream regulator of AMPK activity, fundamentally redefining its role in cellular stress adaptation. This feedback mechanism elucidates why certain genetic alterations, such as co-mutation of STK11 and KEAP1, may be selected for during tumor evolution, providing a more nuanced model for metabolic and oxidative stress resilience in cancer cells (reference study).

Methods and Experimental Design Insights

Choi et al. employed a multifaceted approach integrating molecular, biochemical, and cellular assays in both mouse embryonic fibroblasts (MEFs) and cancer cell lines. Key techniques included immunoblotting for phosphorylation and expression analyses, immunoprecipitation to dissect protein–protein interactions, and confocal microscopy to visualize subcellular localization of key complexes. The study leveraged pharmacological inhibitors and genetic knockdown strategies to parse the roles of AMPK, SQSTM1/p62, and TAK1 (MAP3K7) in the signaling network. Lysosomal function was perturbed using bafilomycin A1 and concanamycin A, while metabolic stress was modeled by glucose deprivation. Site-directed mutagenesis of SQSTM1 enabled functional interrogation of specific phosphorylation sites (notably S24 and S226), and the effects of lactic acid supplementation and ROS modulation were systematically assessed. The tight integration of metabolic, signaling, and autophagic readouts enabled robust mapping of feedback mechanisms.

Core Findings and Why They Matter

The study's central findings include:

• Metabolic stress increases both the expression and phosphorylation of SQSTM1/p62, which is necessary for the activation of AMPK and NFE2L2/NRF2 (reference).
• SQSTM1/p62 enables dual activation by: (1) promoting macroautophagic degradation of KEAP1 (thus releasing NFE2L2/NRF2) and (2) facilitating the assembly of the AXIN–STK11–AMPK complex at the lysosomal membrane, thereby activating AMPK.
• Conversely, AMPK activity is required for the metabolic stress-induced upregulation and phosphorylation of SQSTM1/p62, establishing a double-positive feedback loop.
• Mechanistically, SQSTM1 expression is regulated via PPP2/PP2A-dependent dephosphorylation of TFEB/TFE3, a process triggered by lysosomal deacidification under low glucose and AMPK-dependent proton reduction.
• SQSTM1 phosphorylation at S24 and S226 is specifically increased by TAK1 (MAP3K7), which is activated by ROS and lysosomal Ca²⁺ release.
• Lactic acid–mediated proton provision can abrogate the effects of metabolic stress, highlighting the importance of lysosomal pH in the feedback circuit.

Collectively, these findings clarify the molecular adaptations that enable tumor cells to withstand metabolic and oxidative stress, shedding light on potential vulnerabilities for therapeutic intervention. The dual activation mechanism also helps explain the prevalence of co-occurring STK11 and KEAP1 mutations in certain NSCLCs.

Comparison with Existing Internal Articles

While the reference study focuses on the endogenous feedback network between AMPK and SQSTM1/p62, several internal articles extend these mechanistic insights to experimental tool development and protocol optimization:

• The article "AMPK–SQSTM1 Feedback Loop Drives Dual Antioxidant Activation in Stress" offers a concise summary of the feedback loop, echoing the current study’s core findings and emphasizing new experimental strategies for tumor biology.
• Studies such as "(5Z)-7-Oxozeaenol: Applied TAK1 Inhibition for Inflammation Models" and "Advanced TAK1 Inhibition and Metabolic Stress Integration" highlight the role of TAK1 (MAP3K7) in SQSTM1 phosphorylation and downstream signaling, providing detailed protocols for using TAK1 inhibitors to dissect these pathways in both inflammation and metabolic stress models.
• Internal discussions on precision TAK1 inhibition underline the importance of selectivity and workflow validation for researchers aiming to probe NF-κB and JNK/p38 MAPK pathways, both of which are downstream of TAK1 and implicated in the reference study’s mechanisms.

These resources collectively bridge the gap between mechanistic discovery and practical experimental implementation, reinforcing the centrality of TAK1 and its modulators in untangling stress adaptation networks.

Limitations and Transferability

Several limitations are inherent to the current study. Most experiments were conducted in murine or established cancer cell lines; while these offer valuable mechanistic insight, they may not fully recapitulate the complexity of human tumor microenvironments. The interplay among metabolic stress, autophagy, and antioxidant signaling is highly context-dependent, influenced by cancer cell genotype and metabolic profile. Additionally, the feedback loop’s therapeutic exploitability remains to be validated in vivo, especially in genetically diverse models. Transferability of these findings to primary tumors or other disease contexts should therefore be approached with careful validation and comparative studies.

Protocol Parameters

• Metabolic stress induction: Glucose deprivation (typically 1–12 hours) is used to model energy stress and trigger AMPK–SQSTM1 feedback activation.
• Lysosomal pH modulation: Bafilomycin A1 or concanamycin A can be applied (10–100 nM, 2–6 hours) to perturb lysosomal acidification and facilitate pathway analysis.
• TAK1 inhibition: Selective inhibitors such as (5Z)-7-Oxozeaenol are commonly used at 100–500 nM in cell culture for 12–24 hours to dissect MAP3K7-dependent SQSTM1 phosphorylation and downstream pathway effects (internal protocol reference).
• Phosphorylation analysis: Use of site-directed mutagenesis (e.g., S24A or S226A SQSTM1 mutants) can confirm functional roles of specific phosphorylation sites.
• Antioxidant response measurement: Assess NRF2 target gene expression (e.g., NQO1, GCLC) as a readout for NFE2L2 pathway activation.

Research Support Resources

For investigators seeking to interrogate TAK1’s role in the AMPK–SQSTM1 feedback circuit, (5Z)-7-Oxozeaenol (SKU B7443) is a potent and selective TAK1 inhibitor. Its use enables precise dissection of NF-κB and JNK/p38 MAPK signaling in cell-based and animal inflammation models, as confirmed in both the internal protocol literature and product documentation. For optimal results, follow storage and handling guidelines provided by APExBIO, and tailor inhibitor concentrations to your specific model system.